Latest News

NorCal CarciNET Community is once again working with the Society of Nuclear Medicine and Molecular Imaging (SNMMI) to host a free Patient Education Day during the Society's annual meeting in San Diego on June 12th, 2016. This day long patient centered program is will cover the history and safety and future of nuclear medicine. There will also be a NET breakout, that will focus exclusively on Neuroendocrine Tumors, imaging and treatment.

There is no charge for registration, which also includes access to all SNMMI sessions Saturday - Tuesday. To view all NET related session click here and proceed to June's calendar.

AAA Opens Lutathera Expanded Access Program In U.S. to Eligible Patients And Announces Forthcoming NDA Filing to FDA and EMA.

AAA today announced that the company has initiated an expanded access program (EAP) in the United States for the investigational product, Lutathera. Through the program, Lutathera is being made available for patients suffering from inoperable, somatostatin receptor positive, midgut carcinoid tumors, progressive under somatostatin analogue therapy. Healthcare professionals and patients can learn more about the Lutathera EAP by visiting www.clinicaltrials.gov (trial number: NCT02705313). To read more visit AAA's website.

2016 Neuroendocrine Tumor Patient Conference
Hosted by:UCSF Helen Diller Family Comprehensive Cancer Center
In cooperation with NorCal CarciNET Community, NET Research Foundation, Stanford University Medical Center

Sunday, January 24, 2016 - 9:00 am to 4:30 pm

View the recording of the LiveStream

On October 20, 2015 the Society for Nuclear Medicine and Molecular Imaging and the NorCal CarciNET Community hosted a webinar on PRRT featuring Dr. Ed Wolin and Dr. Eric Mittra. NorCal CarciNET's Josh Mailman facilitated the ensuing question and answer session. Over 95 participated in the webinar which can be viewed below. In addition the slides that were used are available by clicking here. Guidelines for the use of PRRT are avialble from the PRRTInfo.org website.

You may use the share icon (looks like an airplane) to embed this video in another site.

In addition to the NETTER1 trial presented at the European Cancer Congress, two other phase 3 NET clinical trials presented their results.

Everolimus conferred a statistically significant and clinically meaningful PFS benefit with an acceptable safety profile in patients with advanced, progressive neuroendocrine tumors of the lung or gastrointestinal region, according to phase 3 trial results (Radiant4).

The results from the first large scale randomized control trial of PRRT were released today in Vienna, Austria showing increased progression free survival compared to high dose octreotide LAR.

PRRT while available in many parts of the world has not yet been approved for use pending prospective randomized clinical trails (RCT). Having a positive RCT for PRRT will greatly expand access and availability to PRRT around the world. Click here to download the full release.

At the European Cancer Conference in Vienna at the end of September 2015 - Two late breaking abstracts have been selected for presentation at the prestigious Presidential Session on Sunday, September 27, 2015. (Click here to download session PDF)

LATE-BREAKING ABSTRACT: Everolimus in advanced nonfunctional neuroendocrine tumors (NET) of lung or gastrointestinal (GI) origin: Efficacy and safety results from the placebo-controlled, double-blind, multicenter, Phase 3 RADIANT-4 study
Speaker: J. Yao (USA)

LATE-BREAKING ABSTRACT: 177-Lu-Dotatate significantly improves progression-free survival in patients with mid gut neuroendocrine tumours: Results of the phase III NETTER-1 trial
Speaker: P. Ruszniewski (France)

NorCal CarciNET will be in Vienna and will post updates on these important developments as well as other topics of interest for those living with NETS.

On August 3, 2015, Lexicon Pharmaceuticals, Inc. announced that the pivotal TELESTAR Phase 3 clinical trial met its primary endpoint, showing the benefit of oral telotristat etiprate in treating cancer patients with carcinoid syndrome that is not adequately controlled by the current standard of care. Telotristat etiprate was discovered using Lexicon’s gene science, based on Nobel Prize-winning technology, and is the company’s first discovery to complete a pivotal Phase 3 clinical trial. If approved, telotristat etiprate would be the first oral treatment successfully developed for carcinoid syndrome and the first addition to the standard of care in more than 16 years.

JoshSNMMI On June 8, 2015, Josh Mailman, patient advocate, and president of the NorCal CarciNET Community, was honored with the 2015 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Presidential Distinguished Service Award. The award reads, "For substantial contributions to the SNMMI patient outreach program and leadership of the Patient Advocacy Advisory Board (PAAB)."

Thanks to grants from Caring for Carcinoid Foundation and Carcinoid Cancer Foundation, the Saturday sessions (March 14) at the 3rd Theranostics Congress will be free of charge for patients.

To learn more about the conference visit the conference website.

Funding was provided by NorCal CarciNET Community for recording the entire 3rd Theranostics World Congress.

To see the entire patient program click here.

Patient Education Day - SNMMI 2016

Lutathera Expanded Access Program In U.S. Now Open

2016 Bay Area Neuroendocrine Patient Conference - Hosted by UCSF

SNMMI / NorCal CarciNET PRRT Webinar

Updates from ESMO

Results from first large scale PRRT trial released

Two NET Abstracts Set for Presentation at Presidential Session of ECC 2015

Lexicon Reports Positive Top-Line Results for Phase 3 Telotristat Etiprate Study

NorCal CarciNET President awarded

Patient Program at 3rd Theranostic World Congress